Understanding UPB1: A Potential Drug Target (G51733)

Target Name: UPB1

NCBI ID: G51733

UPB1

Understanding UPB1: A Potential Drug Target

UPB1 (Beta-ureidopropionase) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and pancreas. It is an enzyme that is involved in the breakdown of a hormone called ureidopropionate, which is produced by the body and helps regulate various physiological processes.

In recent years, scientists have been interested in studying UPB1 because of its potential as a drug target. This is because the activity of UPB1 has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the reasons why UPB1 is thought to be a potential drug target is that it is involved in the production of ureidopropionate, which is a key metabolite that has been shown to have a variety of pharmacological activity. Ureidopropionate has been shown to be involved in a number of cellular processes, including cell signaling, neurotransmission, and inflammation.

In addition, UPB1 is also involved in the regulation of cellular processes that are important for the development and progression of cancer. Studies have shown that UPB1 is involved in the regulation of cell proliferation, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

Another potential reason why UPB1 is a drug target is because it is involved in the regulation of neurotransmission. Ureidopropionate has been shown to play a role in the regulation of neurotransmitter release from neurons, which is important for the function of the nervous system.

In addition, UPB1 is also involved in the regulation of inflammation. Studies have shown that UPB1 is involved in the production of pro-inflammatory cytokines, which can contribute to the development of inflammatory diseases.

Overall, UPB1 is a protein that is involved in a variety of cellular processes that are important for the health and function of the body. As a result, it is a potential drug target that could be targeted by small molecules or other therapeutic agents. Further research is needed to fully understand the role of UPB1 in disease and to develop effective treatments.

Protein Name: Beta-ureidopropionase 1

Functions: Catalyzes a late step in pyrimidine degradation (PubMed:22525402, PubMed:24526388). Converts N-carbamoyl-beta-alanine (3-ureidopropanoate) into beta-alanine, ammonia and carbon dioxide (PubMed:10542323, PubMed:11508704, PubMed:10415095, PubMed:29976570, PubMed:22525402, PubMed:24526388). Likewise, converts N-carbamoyl-beta-aminoisobutyrate (3-ureidoisobutyrate) into beta-aminoisobutyrate, ammonia and carbon dioxide (Probable)

The "UPB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UPB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets